Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.41 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | PDE9A | O76083 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2739927 | 0.87 | DPP4 (0.54) | DPP4DPP7CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL25446997 | 0.87 | CHRNB2 (0.38) | DPP4DPP7CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL27390228 | 0.85 | DPP4 (0.38) | DPP4DPP7CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL16886278 | 0.84 | CHRNB2 (0.36) | DPP4DPP7CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL19755878 | 0.82 | CHRNB2 (0.41) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL21028193 | 0.82 | CYP1A2 (0.44) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL25815899 | 0.81 | DPP4 (0.38) | DPP4DPP7EPHX2MEN1ALDH1A1 | |
| SCHEMBL18212339 | 0.81 | CHRNB2 (0.34) | DPP4DPP7CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL12259449 | 0.80 | CHRNB2 (0.39) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL13751427 | 0.80 | CHRNB2 (0.39) | DPP4CHRNB2CHRNA3CHRNA4CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026479-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20230339964-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | NUVATION BIO INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339964-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | NUVATION BIO INC (US) | 2023-10-26 | — | — | US | disclosed |
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-20230145481-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | DICE ALPHA, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230141212-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | DICE ALPHA, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230145481-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | DICE ALPHA, INC. | 2023-05-11 | — | — | US | disclosed |
| US-11584756-B2 | Heterocyclic compounds as BET inhibitors | NUVATION BIO INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20090099170-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090012080-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-7345178-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRTIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012080-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | DPP4 1525/4885DPP7 1512/4885CHRNB2 3635/4885 |
| US-11584756-B2 | Heterocyclic compounds as BET inhibitors | BET1, BRD4, BRD3 | DPP4 3146/4885DPP7 2454/4885CHRNB2 2784/4885 |
| US-20090099170-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | DPP4 1525/4885DPP7 1512/4885CHRNB2 3635/4885 |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRT2, SIRT1, SIRT3 | DPP4 1992/4885DPP7 986/4885CHRNB2 2017/4885 |
| US-20230145481-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | IL17A, IL2, IL23R | DPP4 3830/4885DPP7 2096/4885CHRNB2 4733/4885 |
| US-20230141212-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | IL17A, IL2, IL23R | DPP4 3830/4885DPP7 2096/4885CHRNB2 4733/4885 |
| US-20230339964-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | BET1, BRD4, BRD3 | DPP4 3146/4885DPP7 2454/4885CHRNB2 2784/4885 |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRT1, SIRT3, SIRT2 | DPP4 603/4885DPP7 440/4885CHRNB2 3277/4885 |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRT2, SIRT1, SIRT3 | DPP4 1889/4885DPP7 984/4885CHRNB2 2021/4885 |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | DPP4 1230/4885DPP7 880/4885CHRNB2 3689/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | DPP4 3183/4885DPP7 2366/4885CHRNB2 4666/4885 |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | DPP4 1230/4885DPP7 880/4885CHRNB2 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.